Acurx Pharmaceuticals logo
Acurx Pharmaceuticals
ACXP | NASDAQ
Chart Builder DCF Calculator
$0.94
-$0.02 (-2.08%)
At close: Nov 16, 2026, 4:00 PM ET
$1.04
+$0.10 (+10.64%)
After-hours: Nov 16, 2026, 7:36 PM ET

Acurx Pharmaceuticals Company Profile

Company profile explained

Company Profile

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

Key Executives

Name Position
David Luci Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director
Robert G. Shawah Co-Founder & Chief Financial Officer
Michael H. Silverman FACR Medical Director
Robert J. DeLuccia Co-Founder & Executive Chairman

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 16, 2026 8-K Current Report
Sep 17, 2026 EFFECT Filing
Sep 17, 2026 424B3 Filing
Sep 08, 2026 S-1 Filing
Sep 01, 2026 ARS Filing
Sep 01, 2026 DEFA14A Filing
Sep 01, 2026 DEF 14A Filing
Aug 13, 2026 10-Q Quarterly Report
May 12, 2026 424B3 Filing
View All SEC Filings ➞
Acurx Pharmaceuticals
Acurx Pharmaceuticals logo
Country United States
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO David Luci

Contact Details

259 Liberty Avenue Staten Island, New York 10305 United States

Stock Details

Ticker Symbol ACXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001736243
CUSIP Number 00510M203
ISIN Number US00510M2035
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.